Comparison
Both are GHRPs, synthetic ghrelin receptor agonists that stimulate pulsatile growth hormone secretion from the pituitary. Hexarelin is the most potent GHRP available, producing the largest acute GH pulse; ipamorelin is the most selective, stimulating GH without meaningful cortisol, prolactin, or ACTH elevation. These profiles make them suited to different research objectives.
| Attribute | Ipamorelin | Hexarelin |
|---|---|---|
| Class | GHRP (Growth Hormone Releasing Peptide); ghrelin receptor agonist | GHRP (Growth Hormone Releasing Peptide); ghrelin receptor agonist |
| Mechanism | Selective GHS-R1a agonist; stimulates GH pulse with minimal off-target receptor activity | Potent GHS-R1a agonist; also binds CD36 (cardiovascular receptor); elevates cortisol and prolactin |
| GH pulse potency | Moderate; selective without desensitisation at research doses | Highest of all GHRPs; significant desensitisation with repeated use |
| Cortisol elevation | Minimal to none at research doses | Significant; raises cortisol and ACTH |
| Prolactin elevation | Minimal to none at research doses | Significant; raises prolactin |
| Desensitisation | Low; receptor response maintained with repeated use | High; rapid tachyphylaxis with repeated daily administration |
| Half-life | ~2 hours | ~2 hours |
| Commonly reported doses | 100–300 mcg per dose, 1–3× daily SubQ | 100–200 mcg per dose, 1–3× daily SubQ |
| Unique receptor activity | GHS-R1a only | GHS-R1a + CD36 (cardiac research relevance) |
The defining distinction between ipamorelin and hexarelin is the tradeoff between potency and selectivity. Hexarelin produces the highest acute GH pulse amplitude of any GHRP, but its potency comes with costs: significant cortisol and prolactin elevation, meaningful ACTH release, and rapid receptor desensitisation (tachyphylaxis) with repeated daily administration, meaning its GH-stimulating effect diminishes substantially over days to weeks of continuous use. Ipamorelin produces a smaller acute GH pulse but is notable in the research literature for its selectivity: at research doses, it does not meaningfully elevate cortisol, prolactin, or ACTH, and its receptor response is maintained with repeated use.
Hexarelin has a second receptor target with distinct research implications: CD36, a scavenger receptor expressed on cardiac myocytes, macrophages, and endothelial cells. Research has investigated hexarelin's potential role in cardioprotection through CD36-mediated pathways, independent of its GH-stimulating activity. This cardiovascular biology has no equivalent in ipamorelin's pharmacological profile and constitutes a separate area of research interest for hexarelin.
Desensitisation profiles also diverge significantly. Ipamorelin can be administered multiple times daily over extended periods without substantial loss of GH-stimulating effect. Hexarelin's receptor desensitisation means its usefulness for sustained GH axis stimulation is limited; it is more relevant for studies specifically investigating the tachyphylaxis and ceiling effects of the ghrelin receptor system, or for acute single-dose GH pulse studies where desensitisation is not yet relevant.
Both ipamorelin and hexarelin are synthetic peptides that act as agonists at the GHS-R1a (growth hormone secretagogue receptor 1a), also known as the ghrelin receptor. GHS-R1a is expressed on pituitary somatotrophs; its activation triggers pulsatile GH secretion through a mechanism independent of the GHRH receptor pathway. This complementary pathway to GHRH means GHRPs can be co-administered with GHRH analogues for synergistic GH pulse amplification.
The critical mechanistic difference lies in off-target receptor activity. Ipamorelin was specifically engineered to minimise activity at receptors responsible for cortisol, prolactin, and ACTH release. Research at the time of its development documented that older GHRPs (including hexarelin, GHRP-2, and GHRP-6) produced significant HPA and HPL axis stimulation as off-target effects; ipamorelin's selectivity profile was an explicit design objective. Hexarelin retains substantial off-target activity, raising cortisol, ACTH, and prolactin at doses that produce meaningful GH stimulation.
Ipamorelin research has investigated its potential role in:
Hexarelin research has investigated its potential role in:
Both compounds have short half-lives (~2 hours) and require multiple daily injections for sustained GH axis stimulation:
Ipamorelin, Reported side effects in research and anecdotal accounts include transient flushing, mild headache, and injection site reactions. The notable feature of ipamorelin's profile is the absence of significant cortisol or prolactin elevation, which is not a side effect but a pharmacological characteristic relevant to research design.
Hexarelin, Reported side effects in research and anecdotal accounts include cortisol elevation (the most researched off-target effect), prolactin elevation, ACTH release, flushing, and fatigue. Cortisol elevation is a pharmacological consequence of hexarelin's off-target receptor activity and is a primary reason ipamorelin was developed as a more selective alternative. Rapid desensitisation is also reported, particularly with continuous daily dosing.
Ipamorelin and hexarelin are not typically co-administered. Both act on the same GHS-R1a receptor, and combining two GHRPs at the same receptor provides no meaningful additive GH stimulation while compounding hexarelin's side effects (cortisol, prolactin, desensitisation risk). Researchers generally select one GHRP and pair it with a GHRH analogue (such as CJC-1295 or Sermorelin) for the synergistic combination that the literature more commonly reports.
Research contexts commonly favour ipamorelin when the goal is sustained GH axis stimulation without HPA or HPL axis activation, when cortisol and prolactin must be excluded as confounding variables, or when the research context extends over multiple weeks where tachyphylaxis would undermine hexarelin's utility. Its combination with CJC-1295 is one of the most commonly reported GH axis research stacks.
Research contexts favouring hexarelin include investigations specifically into GHS-R1a ceiling effects and desensitisation mechanisms, studies where maximum acute GH pulse amplitude is the outcome variable, or research into CD36-mediated cardioprotection where hexarelin's unique receptor activity is the explicit focus rather than a side effect.
In terms of acute GH pulse amplitude, yes: hexarelin produces the largest acute GH peak of any GHRP in the research literature. However, this potency declines rapidly with repeated use due to tachyphylaxis. Ipamorelin produces a smaller acute pulse but maintains that response over extended use periods. Which is more useful depends on the research objective: peak acute potency vs sustained response over time.
CD36 is a multifunctional scavenger receptor expressed on cardiac myocytes, macrophages, and endothelial cells, with roles in fatty acid uptake, oxidised LDL recognition, and angiogenesis. Research has investigated hexarelin's CD36 binding for its potential role in cardioprotection, including studies in models of cardiac ischemia and heart failure. This activity is completely independent of hexarelin's GHS-R1a-mediated GH effects, making hexarelin uniquely relevant for cardiovascular peptide research in a way that ipamorelin is not.
Water retention is associated with elevated IGF-1 and GH levels generally, and ipamorelin does raise GH and therefore IGF-1 over time. Anecdotal reports suggest mild fluid retention similar to other GHRPs at comparable GH-stimulating doses. This is a downstream GH effect common to the class rather than specific to ipamorelin or hexarelin individually.
GHRP-2 is roughly comparable to hexarelin in potency but slightly less prone to desensitisation; it raises cortisol and prolactin similarly. GHRP-6 raises cortisol and prolactin and also strongly stimulates appetite via hypothalamic feeding pathways. Ipamorelin is considered the most selective of the four compounds, with the smallest off-target receptor profile. Hexarelin is the most potent acutely but the least suitable for sustained protocols.